DR6 (death receptor 6), also known as CD358, is a single-pass, type I transmembrane glycoprotein in the TNF receptor superfamily (TNFRSF21). DR6 contains an extracellular domain (ECD) with 4 TNFR cysteine-rich repeats and a palmitylated cytoplasmic region with 1 death domain (DD). DR6 is expressed in most human tissues with the highest levels in heart, brain, placenta, pancreas, thymus, lymph node and several non-lymphoid cancer cell lines. Among hematopoietic cells, DR6 is expressed on monocytes, resting CD4+ T cells, and pro-, pre-, and naïve B cells. DR6 interacts with the adaptor protein TRADD and mediates signal transduction through its death domain. Expression of DR6 in mammalian cells induces the activation of NF-κB and JNK pathways as well as apoptosis. DR6 acts as an important regulatory molecule in T cell activation, and is involved in inflammation. DR6-defieicent mice have enhanced CD4+ T cell proliferation and are resistant to induced airway inflammation and experimental autoimmune encephalitis. DR6 is constitutively expressed on some prostate cancer cells and can be induced by TNF-α on other cytokines. DR6 is uniquely cleaved from tumor cell surface by the membrane- associated matrix metalloproteinase that is associated with tumor malignancy. DR6 is also expressed on developing neurons where it can bind APP fragment that is generated following deprivation of neurotrophic factors. APP binding to DR6 triggers DR6-mediated axonal pruning..

DR6 (death receptor 6), also known as CD358, is a single-pass, type I transmembrane glycoprotein in the TNF receptor superfamily (TNFRSF21). DR6 contains an extracellular domain (ECD) with 4 TNFR cysteine-rich repeats and a palmitylated cytoplasmic region with 1 death domain (DD). DR6 is expressed in most human tissues with the highest levels in heart, brain, placenta, pancreas, thymus, lymph node and several non-lymphoid cancer cell lines. Among hematopoietic cells, DR6 is expressed on monocytes, resting CD4+ T cells, and pro-, pre-, and naïve B cells. DR6 interacts with the adaptor protein TRADD and mediates signal transduction through its death domain. Expression of DR6 in mammalian cells induces the activation of NF-κB and JNK pathways as well as apoptosis. DR6 acts as an important regulatory molecule in T cell activation, and is involved in inflammation. DR6-defieicent mice have enhanced CD4+ T cell proliferation and are resistant to induced airway inflammation and experimental autoimmune encephalitis. DR6 is constitutively expressed on some prostate cancer cells and can be induced by TNF-α on other cytokines. DR6 is uniquely cleaved from tumor cell surface by the membrane- associated matrix metalloproteinase that is associated with tumor malignancy. DR6 is also expressed on developing neurons where it can bind APP fragment that is generated following deprivation of neurotrophic factors. APP binding to DR6 triggers DR6-mediated axonal pruning..

  

Product Details

 

Gene Symbol: TNFRSF21; CD358; BM-018; UNQ437/PRO868

  

NCBI Gene ID: 27242

 

Uniprot Entry: O75509

 

Construct Details: The recombinant human DR6-Fc fusion is expressed as a 536 amino acid protein consisting of Gln42 - His349 region of DR6 (UniProt accession #O75509) and a C-terminal Fc from human IgG1, which exists as a dimer/tetramer under non-reducing conditions (see the gel image inserted above).  

   

Source: Human cells stably expressing human DR6-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

        10         20         30         40         50         60 

QPEQKASNLI GTYRHVDRAT GQVLTCDKCP AGTYVSEHCT NTSLRVCSSC PVGTFTRHEN 

        70         80         90        100        110        120 

GIEKCHDCSQ PCPWPMIEKL PCAALTDREC TCPPGMFQSN ATCAPHTVCP VGWGVRKKGT 

       130        140        150        160        170        180 

ETEDVRCKQC ARGTFSDVPS SVMKCKAYTD CLSQNLVVIK PGTKETDNVC GTLPSFSSST 

       190        200        210        220        230        240 

SPSPGTAIFP RPEHMETHEV PSSTYVPKGM NSTESNSSAS VRPKVLSSIQ EGTVPDNTSS 

       250        260        270        280        290        300 

ARGKEDVNKT LPNLQVVNHQ QGPHHRHILK LLPSMEATGG EKSSTPIKGP KRGHPRQNLH 

       310        320        330        340        350        360 

KHFDINEHST GTHTCPPCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP 

       370        380        390        400        410        420 

EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP 

       430        440        450        460        470        480 

IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 

       490        500        510        520        530 

KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 

 

 

M.W.: Calculated molecular mass (kDa): 59; Estimated by SDS-PAGE under reducing condition (kDa): 75-85

 

Calculated PI: 8.22

 

Calculated extinction coefficients (M-1 cm-1, at 280nm): 53870

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free).

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds to human APP or APLP2.

 

 

  

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

 

1. FEBS. Lett. 431: 351 (1998). 

2. J. Exp. Med. 194: 1441 (2001). 

3. Oncogene. 20: 7965 (2001). 

4. Immunity 15:23 (2001)

5. J. Immunol. 169: 3993 (2002). 

6. Nature 457:981 (2009).

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL0280-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.